drugset / Trial / NCT01105117

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

NCT01105117

Phase 4 Completed 2 enrolled Actelion
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.

Timeline

Start
2010-05
Primary completion
2011-07
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator epoprostenol Other / unclassified